Topic: inflammatory diseases
IFM Therapeutics is unveiling its second subsidiary, IFM Due, which will target the cGAS/STING pathway to treat inflammatory and autoimmune disease.
Inflazome has brought on Thomas Jung, M.D., Ph.D., to be its new chief medical officer and lead clinical development of its NLRP3 inhibitors.
Genentech acquired Jecure Therapeutics and its stable of NLRP3 inhibitors for an undisclosed amount.
The agreement covers small molecules designed to treat multiple neurodegenerative and systemic inflammatory diseases.
Newly formed British biotech Sitryx will use the money and its relationship with GSK to move immunometabolism assets toward human testing.
Jared Gollob, M.D., is joining Kymera Therapeutics, a startup focused on protein degradation.
Principia Biopharma has filed to raise up to $86.3 million in its IPO to carry its lead BTK inhibitor into phase 3.
Blocking the signaling receptor NLRP3 could treat a range of autoimmune disorders, IFM researchers believe.
IFM Therapeutics is hiving off its NLRP3 stable into a subsidiary dubbed IFM Tre, which expects to advance its lead asset into phase 1 next year.